Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial - Nature Medicine

Australia News News

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial - Nature Medicine
Australia Latest News,Australia Headlines
  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 39 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 53%

In patients with metastatic triple-negative BreastCancer, atezolizumab + anthracycline-based chemotherapy improves progression-free survival, including in PD-L1 negative disease SABCS22 andreashr GroupKyte AmundJon Oslounivsykehus UniOslo_MED BCsm

In patients who have received adjuvant treatment with anthracyclines or cyclophosphamide, a minimum of 12 months from treatment with anthracyclines or cyclophosphamide until relapse of disease is required.Female patients of childbearing potential should have a negative urine or serum pregnancy test within 7 days before receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

The baseline assessment included a medical history, a full clinical examination, a complete blood count , a comprehensive blood chemistry panel and a cardiac assessment by electrocardiogram and echocardiography. CBC and blood chemistry were repeated on day 1 of each treatment cycle, and a full clinical examination, electrocardiogram and echocardiography were repeated every 4th cycle.

Tumor evaluation by CT of the chest, abdomen and pelvis and a bone scan was performed within 21 days of randomization and repeated every 8 weeks from the first day of treatment for the first 12 months and every 12 weeks thereafter. Response evaluation was done using iRECIST, a version of the RECIST modified to capture the response patterns of immunotherapies

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NatureMedicine /  🏆 451. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae - Nature MedicineMolecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae - Nature MedicineTranscriptomic analyses of acute-phase whole blood from a large cohort of patients with COVID19 identify molecular determinants of post-infection long-term sequelae LongCOVID SARSCoV2 noambeckmann1 aw_charney DarwinAwdWinner
Read more »

Anna Kendrick Stars in Trailer for New Horror Movie Alice, DarlingAnna Kendrick Stars in Trailer for New Horror Movie Alice, DarlingActor Anna Kendrick has starred in a diverse array of projects over the years, which includes [...]
Read more »

Anna Kendrick has the girl's trip from hell in Alice, Darling trailerAnna Kendrick has the girl's trip from hell in Alice, Darling trailerWunmi Mosaku, Kaniehtiio Horn, and Charlie Carrick round out the cast in Mary Nighy's psychological thriller
Read more »

'Alice, Darling' Trailer: Anna Kendrick Is Crushed With Anxiety'Alice, Darling' Trailer: Anna Kendrick Is Crushed With AnxietyAnna Kendrick struggles with an abusive relationship in the new trailer for AliceDarling. Watch it here:
Read more »

Alice, Darling Trailer: Anna Kendrick Leads Psychological ThrillerAlice, Darling Trailer: Anna Kendrick Leads Psychological ThrillerLionsgate has dropped the official Alice, Darling trailer for the upcoming psychological thriller drama starring Anna Kendrick.
Read more »

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study - Nature MedicinePatient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study - Nature MedicineUsing a randomized three-way crossover design and stratification approaches based on obesity and renal function in people with type 2 diabetes, the TriMaster study demonstrated that patients with obesity were more likely to have greater glycemic control with pioglitazone (a thiazolidinedione) than with sitagliptin (a DPP4 inhibitor) and that patients with eGFR 60–90 ml/min/1.73 m2 were more likely to achieve lower HbA1c levels on sitagliptin than on canagliflozin (an SGLT2 inhibitor).
Read more »



Render Time: 2025-02-27 22:30:49